Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome
Science Translational Medicine · 09.08.2023 · 15 (708)
DOI: 10.1126/scitranslmed.abc8226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 09.08.2023. Verfasst von Wen Y Ding und 21 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Renal, Bristol Medical School, Dorothy Hodgkin Building, University of Bristol, Bristol BS1 3NY, UK. Hauptthemen laut MEDLINE: Nephrotic Syndrome, Kidney Diseases. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Medical Research Council, Wellcome Trust, NIMH NIH HHS.
Abstract (Originalsprache)
Gene therapy for kidney diseases has proven challenging. Adeno-associated virus (AAV) is used as a vector for gene therapy targeting other organs, with particular success demonstrated in monogenic diseases. We aimed to establish gene therapy for the kidney by targeting a monogenic disease of the kidney podocyte. The most common cause of childhood genetic nephrotic syndrome is mutations in the podocyte gene NPHS2 , encoding podocin. We used AAV-based gene therapy to rescue this genetic defect in human and mouse models of disease. In vitro transduction studies identified the AAV-LK03 serotype as a highly efficient transducer of human podocytes. AAV-LK03–mediated transduction of podocin in mutant human podocytes resulted in functional rescue in vitro, and AAV 2/9–mediated gene transfer in both the inducible podocin knockout and knock-in mouse models resulted in successful amelioration of kidney disease. A prophylactic approach of AAV 2/9 gene transfer before induction of disease in conditional knockout mice demonstrated improvements in albuminuria, plasma creatinine, plasma urea, plasma cholesterol, histological changes, and long-term survival. A therapeutic approach of AAV 2/9 gene transfer 2 weeks after disease induction in proteinuric conditional knock-in mice demonstrated improvement in urinary albuminuria at days 42 and 56 after disease induction, with corresponding improvements in plasma albumin. Therefore, we have demonstrated successful AAV-mediated gene rescue in a monogenic renal disease and established the podocyte as a tractable target for gene therapy approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Bristol Renal, Bristol Medical School, Dorothy Hodgkin Building, University of Bristol, Bristol BS1 3NY, UK.
- Purespring Therapeutics, Rolling Stock Yard, 188 York Way, London N7 9AS, UK.
- Department of Histopathology, Cheltenham General Hospital, Cheltenham GL53 7AN, UK.
- Laboratoire des Maladies Rénales Héréditaires, Inserm UMR 1163, Institut Imagine, Université Paris Cité, Paris 75015, France.
- Academic Unit of Ophthalmology, Bristol Medical School, Biomedical Sciences Building, University of Bristol, Bristol BS8 1TD, UK.
- Research Department of Haematology, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6BT, UK.
ORCID-Profile: Wen Y Ding, Sarah Hunter, Abigail Lay, Bryony Hayes, Matthew Beesley, Ruth Rollason, Jennifer A Hurcombe, Fern Barrington, Carl May, Jack Tuffin, Timothy Roberts, Geraldine Mollet, Colin J Chu, Jenny McIntosh, Richard J Coward, Corinne Antignac, Moin A Saleem
Förderung
- Medical Research Council
- Wellcome Trust
- NIMH NIH HHS
- Department of Health
Zitieren
APA
Ding, W. Y., Kuzmuk, V., Hunter, S., Lay, A., Hayes, B., Beesley, M., Rollason, R., Hurcombe, J. A., Barrington, F., Masson, C., Cathery, W., May, C., Tuffin, J., Roberts, T., Mollet, G., Chu, C. J., McIntosh, J., Coward, R. J., Antignac, C., …, & Saleem, M. A. (2023). Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome. Science Translational Medicine, 15(708). https://doi.org/10.1126/scitranslmed.abc8226
Vancouver
Ding WY, Kuzmuk V, Hunter S, Lay A, Hayes B, Beesley M, et al. Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome. Science Translational Medicine. 2023;15(708). doi:10.1126/scitranslmed.abc8226
BibTeX
@article{Ding2023,
author = {Ding, Wen Y and Kuzmuk, Valeryia and Hunter, Sarah and Lay, Abigail and Hayes, Bryony and Beesley, Matthew and Rollason, Ruth and Hurcombe, Jennifer A and Barrington, Fern and Masson, Catrin and Cathery, William and May, Carl and Tuffin, Jack and Roberts, Timothy and Mollet, Geraldine and Chu, Colin J and McIntosh, Jenny and Coward, Richard J and Antignac, Corinne and Nathwani, Amit and Welsh, Gavin I and Saleem, Moin A},
title = {Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {708},
doi = {10.1126/scitranslmed.abc8226}
}
EUVIMED